Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long-term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes. The researchers used an adeno-associated viral (AAV) vector to deliver to the mouse pancreas two proteins, Pdx1 and MafA, which reprogrammed plentiful alpha cells into functional, insulin-producing beta cells.
“This study is essentially the first description of a clinically translatable, simple single intervention in autoimmune diabetes that leads to normal blood sugars, and importantly with no immunosuppression,” says senior study author George Gittes of the University of Pittsburgh School of Medicine. “A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.”
Approximately 9% of the world’s adult population has diabetes, which can cause serious health problems such as heart disease, nerve damage, eye problems, and kidney disease. One fundamental goal of diabetes treatment is to preserve and restore functional beta cells, thereby replenishing levels of a hormone called insulin, which moves blood glucose into cells to fuel their energy needs. But in patients with type 1 diabetes, beta-cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.
A potential solution to this problem is to reprogram other cell types into functional beta-like cells, which can produce insulin but are distinct from beta cells and therefore are not recognized or attacked by the immune system. To explore the feasibility of this approach, Gittes and first author Xiangwei Xiao of the University of Pittsburgh School of Medicine engineered an AAV vector to deliver to the mouse pancreas proteins called Pdx1 and MafA, which support beta cell maturation, proliferation, and function. The goal was to generate functional beta-like cells from pancreatic alpha cells, which may be the ideal source for beta cell replacement. For example, alpha cells are plentiful, resemble beta cells, and are in the correct location, all of which could facilitate reprogramming.
By comparing the gene expression patterns of normal beta cells and insulin-producing cells derived from alpha cells, the researchers confirmed nearly complete cellular reprogramming. This gene therapy approach restored normal blood glucose levels in diabetic mice for an extended period of time, typically around four months, and the new insulin-producing cells derived almost exclusively from alpha cells. Moreover, the strategy successfully generated functional insulin-producing cells from human alpha cells.
“The viral gene therapy appears to create these new insulin-producing cells that are relatively resistant to an autoimmune attack,” Gittes says. “This resistance appears to be due to the fact that these new cells are slightly different from normal insulin cells, but not so different that they do not function well.”
Several features of this approach could facilitate translation to humans. For one, AAV vectors like those used in this study are currently undergoing various gene therapy trials in humans. Moreover, the viral vectors can be delivered directly to the human pancreas through a routinely performed non-surgical endoscopic procedure; however, this procedure can elicit pancreatic inflammation. In addition, no immunosuppression is required, so patients would avoid related side effects such as an increased risk of infection.
However, one major concern was that the mice did eventually return to the diabetic state, suggesting that this treatment would not represent a definitive cure for the disease. “The protection from recurrent diabetes in the mice was not permanent, although some studies would suggest that processes in mice are highly accelerated, so four months in mice might translate to several years in humans,” Gittes says.
Currently, the researchers are testing their approach in primates. “If we are able to show efficacy in non-human primates, we will begin work with the FDA to get approval for the use of this viral gene therapy in diabetic patients, both type 1 and type 2,” Gittes says.
The Latest on: Type 1 diabetes
Large Babies Despite Good Control in Type 1 Diabetes Pregnancies
on July 18, 2018 at 8:00 am
Despite good glycemic control with continuous glucose monitoring (CGM) and intensive insulin management throughout pregnancy, women with type 1 diabetes still had babies who were large for gestational ... […]
Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus
on July 18, 2018 at 5:44 am
LAVAL, Quebec, July 18, 2018 (GLOBE NEWSWIRE) -- Altasciences is pleased to have partnered with Xeris Pharmaceuticals, a specialty pharmaceutical company leveraging its novel formulation technology pl... […]
Diabetic Alert Dog Delivered to 6-Year-Old Girl with Type 1 Diabetes Mellitus in Chestertown, MD
on July 18, 2018 at 12:10 am
A 6-year-old girl from Chestertown, Maryland named Brooke received a very special delivery today of her very own, a Diabetic Alert Service Dog from SDWR, a 501c(3) nonprofit organization based in Madi... […]
New Study Explores Effects of Omega-3 Fatty Acids and Vitamin D in Type 1 Diabetes
on July 17, 2018 at 10:51 pm
Scientists from the Diabetes Research Institute at the University of Miami Miller School of Medicine have announced the launch of a new clinical trial that will assess the impact of high-dose omega-3 ... […]
Type 1 diabetes vaccine? New study raises hope, questions
on July 16, 2018 at 6:30 pm
For Hodalis Gaytan, 20, living with Type 1 diabetes means depending on an assortment of expensive medicines and devices to stay healthy. Test strips. Needles. A glucose meter. Insulin. The increasing ... […]
Type 1 Diabetes Drugs 2018-2024 Global Market Outlook by Type, End-User and Region - ResearchAndMarkets.com
on July 16, 2018 at 4:29 am
DUBLIN--(BUSINESS WIRE)--The "Type 1 Diabetes Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The repo... […]
'Groundbreaking' MGH diabetes research catches eye of Gov. Baker, insurers
on July 13, 2018 at 2:00 am
It was 5 o’clock on a Friday afternoon in 2017, days after the latest research on Faustman’s work in diabetes had been released. Faustman had been studying a vaccine that could potentially reverse typ... […]
New type 1 Diabetes clinical trial explores effects of Omega-3 and Vitamin D
on July 11, 2018 at 10:57 am
Scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine today announced the launch of a new clinical trial that will assess the impact of high-dose o... […]
Insurance Gaps Costly for Those With Type 1 Diabetes
on July 11, 2018 at 8:09 am
WEDNESDAY, July 11, 2018 (HealthDay News) -- Gaps in private insurance coverage are common among American adults with type 1 diabetes, raising their risk for health crises, a new study finds. "Type 1 ... […]
How to discuss very low-carbohydrate diets in patients with type 1 diabetes
on July 11, 2018 at 5:19 am
Data appearing in Pediatrics earlier this year showed that children and adults seeking long-term treatment for type 1 diabetes who followed a very-low carbohydrate diet had measures of glycemic contro... […]
via Google News and Bing News